# JM2

Source: https://onco.cc/drugs/jm2/  
OnCo record `jm2` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JM2 is an experimental peptide from Acomhal Research aimed at the stem-like cells that let glioblastoma grow back. It has not yet been tested in people.

## Summary

JM2 is the connexin 43 mimetic peptide that Acomhal Research's 2026 National Cancer Institute STTR award describes; the award abstract reports that it reduced glioblastoma stem cell populations in patient-derived models in vivo, and the award funds delivering it by an alphavirus vector. No registered trial was found.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: Cx43 mimetic peptide
- Tags: pipeline
- Code: JM2
- Modality: Mimetic peptide
- Mechanism: A connexin 43 mimetic peptide that, according to the NIH award abstract, disrupts the interaction of Cx43 with microtubules in glioblastoma stem cells and kills them without affecting normal brain cells.

## Sources

- NIH RePORTER: award 1R41CA306619-01A1: https://reporter.nih.gov/project-details/11409740
- Acomhal Research: glioblastoma: https://acomhal.com/glioblastoma/

## Connected records

- companies: [Acomhal Research](https://onco.cc/companies/acomhal-research/)

---
JSON: https://onco.cc/api/v1/entities/jm2.json